Radioembolization with 90 Y microspheres represents a novel transarterial radiation treatment for liver tumors. The purpose of this pilot study was to evaluate the findings of postimplantation PET/CT of 90 Y glass microspheres. Methods: Three patients with hepatocellular carcinoma and 2 patients with liver metastases (1 neuroendocrine, 1 colorectal) underwent PET/CT after radioembolization. Four patients underwent imaging at 1 mo to assess response and confirm PET/CT findings; 1 patient underwent PET/CT at 4 d after 90 The tracer 90 Y is traditionally thought of as a pure b-emitter. Thus, current clinical practice involves determining the distribution of the microspheres through bremsstrahlung imaging combined with anatomic imaging via SPECT/CT (1). Because bremsstrahlung imaging is based on a SPECT acquisition that uses either a wide imaging window or multiple energy windows due to the continuum, the scattered photon cannot easily be distinguished from true photons. Consequently, bremsstrahlung imaging is not quantifiable, and thus accurate dose distribution cannot be obtained (2).
The tracer 90 Y is traditionally thought of as a pure b-emitter. Thus, current clinical practice involves determining the distribution of the microspheres through bremsstrahlung imaging combined with anatomic imaging via SPECT/CT (1) . Because bremsstrahlung imaging is based on a SPECT acquisition that uses either a wide imaging window or multiple energy windows due to the continuum, the scattered photon cannot easily be distinguished from true photons. Consequently, bremsstrahlung imaging is not quantifiable, and thus accurate dose distribution cannot be obtained (2) .
In an effort to improve pretreatment evaluation and follow-up, microspheres containing radionuclides that emit both b-and g-radiations have been proposed, and treatment with microspheres includes the use of 166 Ho and 186 Re/ 188 Re. At the time of this article's publication, glass and poly (L-lactic acid) (PLLA) microspheres incorporating 186 Re/ 188 Re had not been tested in human subjects with liver tumors. However, 188 Re human serum albumin microspheres ( 188 Re-HSAM) have been tested in a small cohort of patients at a single institution (3) . The maximum b-particle energy of 188 Re (2.12 MeV) is lower than that of 90 Y (2.28 MeV), thus necessitating 4-to 5-fold-higher activities to obtain an absorbed dose equivalent to that of 90 Y. Because the g-energy (155 keV) is comparable to other nuclear medicine imaging agents, 188 Re-HSAM seems to be a good candidate for radioembolization of liver tumors. However, no conclusive effects could be derived from the study performed by Liepe et al. because of the small cohort size and heterogeneity of the patients' primary disease (3). To properly evaluate the effect of radioembolization of hepatic malignancies with 188 Re-HSAM, more studies and a larger patient cohort are warranted.
Another promising radionuclide proposed for radioembolization of hepatic tumors is 166 Ho (maximum energy of the b-particle, 1.77 [48.7%] and 1.85 [50.5%] MeV and energy of the g-ray, 81 keV [6.7%] ). 166 Ho PLLA microspheres are currently being used in patients with hepatic malignancies under a phase I clinical trial (4, 5) . Similar to the 188 Re HSAM dosimetry, the absorbed radiation dose per activity of 166 Ho (8.7 mGy/MBq) is lower than that of 90 Y (28 mGy/MBq). As a result, with 166 Ho 3 times the radioactivity will be required for radioembolization to achieve a dosimetry equivalent to that of 90 Y. The greatest advantage of 166 Ho is that it represents a multimodality imaging agent (6) . The paramagnetic properties of 166 Ho allow 166 Ho PLLA to show a high transverse relaxation rate that is visualized as dark regions on a T2*-weighted MR image (7) . Moreover, the 166 Ho x-ray attenuation coefficient is sufficiently high enough to be used as a contrast agent for visualization through CT (6) . The greatest disadvantage of 166 Ho PLLA is the relatively short half-life of the tracer, meaning that each dose will require separate neutron irradiation and a short logistic timeline to get the dose from the reactor to the patient (8) .
However, for 90 Y the internal pair production (positron) branching ratio for the 01-01 transition of 90 (11) . Unfortunately, time-of-flight PET/CT is not commonly available for many institutions performing radioembolization; alternatively, standard PET/CT is more easily accessible. Consequently, we postulated that standard PET/CT would successfully assess the biodistribution of 90 Y glass microspheres (TheraSphere; MDS Nordion) that were administered for the treatment of hepatic tumors.
MATERIALS AND METHODS

Patient Sample
Three patients with hepatocellular carcinoma (HCC) and 2 patients with liver metastases underwent dedicated whole-body PET/CT after radioembolization for their liver tumors. The technical details for radioembolization have been discussed in detail elsewhere (12) . Briefly, all patients underwent pretreatment diagnostic angiography with 99m Tc-labeled macroaggregated albumin ( 99m Tc-MAA). Subsequently, all were treated with 90 Y glass microspheres and underwent immediate post-90 Y implantation PET/CT within 2 h of treatment. Our institution does not require review board approval for case reports. The activity administered and location of injection for each patient are described in Table 1 .
Diagnostic Arterial Imaging
As part of the routine diagnostic work-up for radioembolization, all patients were administered approximately 74 MBq of 99m Tc-MAA via a microcatheter positioned in a branch of the hepatic artery at 2 wk before treatment. Arterial distribution of the particles was quantified from SPECT/CT fused images that were obtained on the Siemens Symbia T (SPECT/CT) scanner using a 128 · 128 acquisition matrix with 60 frames (angular step, 3°) at a rate of 35 s per frame. Attenuation correction was achieved through the CT acquisition (130 kV, 25 mAs, B30 kernel, and 5-mm slices). Reconstructed images were fused and analyzed with Syngo TrueD (2008 version; Siemens AG).
Immediate Posttreatment 90 Y PET/CT Acquisition Parameters
On the day of treatment with 90 Y, dedicated whole-body PET/CT scans from the chest to just above the pelvis were obtained using the Biograph 40 with Pico-3D, Hi-REZ, and TrueV options (Siemens Medical Solutions USA, Inc.), within 2 h after intraarterial adminis- All patients were positioned on the imaging table with their arms elevated. After the imaging field had been determined with an initial scout scan, an 80-to 110-s whole-body CT scan was acquired using the following parameters: 120 kVp, 40 mA, 1-s tube rotation, 4-mm slice collimation, and an 8-mm/s (i.e., pitch, 2) bed speed. On completion of the CT portion, the PET emission data were acquired for 10 min/bed position for all patients. Imaging included 2 bed positions per patient, with the liver centered between the 2 positions, resulting in whole-body PET emission durations of 20 min. No effort was made to prevent saturation of the detectors from bremsstrahlung x-rays or reduce the noise generated from the LSO crystal.
Y PET/CT Tomographic Reconstruction Parameters
Tomographic images were generated by iterative reconstruction with segmented attenuation correction using the following parameters for the Siemens Biograph 40: True-X; subset, 21; iteration, 3; matrix, 168 · 168; postprocessing filter, 4 mm in full width at half maximum; loop filter, 4 mm in full width at half maximum; and gaussian smooth filter, 4 mm. PET images were analyzed by visual inspection of hepatic metastases using Syngo TrueD. Although the activity distribution could not be derived from these initial images, the tumorto-normal tissue average counts (TN) were assessed from a volume region of interest drawn on the PET/CT images and compared with a TN obtained from the SPECT/CT images of the 99m Tc-MAA distribution in 2 cases. 
RESULTS
Patients
All patients underwent successful treatment without any reportable or recordable medical events. In the 4 patients with imaging follow-up at 1 mo, treatment effect was confirmed. In the 3 patients with HCC, the absence of contrast enhancement suggested complete tumor necrosis. In the patient with metastatic colorectal cancer, carcinoembryonic antigen decreased from 18 to 5, with the posttreatment CT scan confirming decreased tumoral contrast enhancement and size.
Figures 1-4 represent 4 different patients for whom PET/ CT images show an area of increased activity reflecting the biodistribution of 90 Y glass. As is illustrated with diagnostic imaging such as Dyna CT or intraarterially administered 99m Tc-MAA SPECT/CT, the 90 Y glass microsphere radioactivity is preferentially deposited in the tumor. This is quantitatively illustrated by comparing the TN for 2 patients who had similar microcatheter positions for both the 99m Tc-MAA SPECT/CT study and the 90 Y PET/CT study ( Table 2) .
Imaging Technique
Imaging time for all cases was less than 20 min. Because this was a proof of concept analysis, longer acquisition times for possible statistical quantitative data were not explored. The maximum true coincidence counting rate ranged from approximately 124 cps (patient 1) to 308 cps (patient 3). These counting rates are similar to those reported by Nickles et al. (10) .
Adverse Events
There are important reasons for microsphere imaging: to confirm microsphere deposition, predict a tumor response, prevent or mitigate adverse events, and potentially determine TN ratio. This last concept may result in a significant improvement of dosimetry associated with microspheres. None of the 5 patients experienced adverse events related to nontarget deposition, as was consistent with the 90 Y PET images.
DISCUSSION
On the basis of our pilot study, standard PET/CT using LSO scintillation detectors may be used to assess the biodistribution of 90 Y glass microspheres. Our experience suggests that measures reducing signal-to-noise ratio, such as the use of copper shielding or time-of-flight imaging systems, were not required. We obtained TN values that were comparable to the values obtained from the diagnostic arterial studies. Unfortunately, the lutetium element of the crystal contains a trace amount of a naturally long decaying radioactive isotope ( 176 Lu), which will provide some background counting rate that needs to be corrected before any quantitative assessment is performed.
Imaging patients who have been administered 90 Y glass microspheres using a PET/CT system has the potential to greatly improve treatment planning by confirming the biodistribution of the microspheres with a resolution range of 2.5-4 mm. Physicians may be able to improve treatment outcomes using the PET/CT image to determine alternative supplying vessels, thus providing better tumor coverage. Although the inaccuracies and quantification techniques appear to be a work in progress, microsphere localization may prove to be a more relevant acute need, because this therapy, without partition modeling, has been shown to be safe.
CONCLUSION
This wider availability of the microsphere imaging technique should contribute to the better understanding of the distribution of microspheres used for radioembolization of hepatic tumors. With the resolution gain from PET/CT and thus the improved accuracy of the dose distribution, future patient treatment outcomes may be improved and patient-specific dosimetric methodologies may be achievable. However, the clearest message from our pilot study appears to be that 90 Y microspheres can be visualized with a simple 20-min PET/CT scan acquired using universally available technology. Postimplantation distribution can now be easily confirmed. 
